SIGA Technologies, Inc.
Financials
Valuation Metrics
SIGA Technologies, Inc.'s Market Cap is $213M. At end of 2025 it was $438M. Ranked #2970 of 3,118 in US market (top 95%), #1355 of 1,474 on NASDAQ (top 92%), #244 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 92%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $213M | US#2,970/3,118 Sec#244/265 |
| Revenue | $54M | US#2,737/3,118 Sec#145/265 |
| Net Income | $-3M | US—/3,118 Sec—/265 |
| Total Assets | $176M | US#3,000/3,118 Sec#248/265 |
| Net Assets | $165M | US#2,715/3,118 Sec#200/265 |
| Employees | 49 | US#2,703/3,118 Sec#209/265 |
| Value | ||
| P/B | 1.29x | US#745/3,118 Sec#34/265 |
| P/S | 3.96x | US#2,097/3,118 Sec#68/265 |
| FCF Yield | -9.64% | US—/3,118 Sec—/265 |
| Profitability | ||
| ROE | -1.67% | US#2,170/3,118 Sec#67/265 |
| ROA | -1.57% | US#2,341/3,118 Sec#78/265 |
| Op. Margin | -20.76% | US#2,579/3,118 Sec#100/265 |
| Revenue Growth | -70.13% | US#2,710/3,118 Sec#170/265 |
| Earnings Growth | -103.35% | US#1,853/3,118 Sec#53/265 |
| Financial Health | ||
| Debt Ratio | 6.32% | US#54/3,118 Sec#25/265 |
| Total Debt | $439397.00 | US#2,981/3,118 Sec#251/265 |
| FCF | $-20M | US#2,414/3,118 Sec#96/265 |
| Cash | $118M | US#2,110/3,118 Sec#161/265 |
| Current Ratio | 21.72x | US#108/3,118 Sec#20/265 |
| Dividend | ||
| Div. Yield | 20.41% | US#22/3,118 Sec#1/265 |
| Div. Growth | 1.06% | US#1,130/3,118 Sec#20/265 |
| Performance | ||
| 1Y Return | -64.19% | US#3,000/3,118 Sec#250/265 |
| 1M Return | -12.28% | US#2,493/3,118 Sec#183/265 |
| From 52W High | -64.95% | US#2,898/3,118 Sec#230/265 |
| 1Y MDD | -65.95% | US#2,863/3,118 Sec#225/265 |
| Trading | ||
| Volume | 651,680 shares | US#2,133/3,118 Sec#206/265 |
| Trading Value | $2M | US#2,951/3,118 Sec#248/265 |
| Per Share | ||
| EPS | $-0.04 | US—/3,118 Sec—/265 |
| BPS | $2.30 | US#2,545/3,118 Sec#169/265 |
Company Info
SIGA Technologies, Inc. is a pharmaceutical company with commercialized products, specializing in the health security and infectious disease sectors across the United States. A core offering is TPOXX, an oral antiviral drug formulated to combat human smallpox, a condition caused by the variola virus. Furthermore, the company has forged a strategic collaboration with Cipla Therapeutics. This partnership aims to ensure ongoing innovation and accessibility of antibacterial treatments, particularly those designed to counter biothreats. Founded in 1995, SIGA Technologies' corporate headquarters are located in New York, New York.